Afatinib · Gilotrif

Small molecule

Also known as BIBW 2992

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
US
  • Previously Treated, Metastatic Squamous NSCLC GILOTRIF is indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy .
Product first approved 2013Outside this platform's coverageFDA label
JP
  • EGFR mutation-positive inoperable or recurrent non-small cell lung cancer (Giotrif tablets, Nippon Boehringer Ingelheim)
Product first approved 2014PMDA
EU
  • Giotrif (afatinib): EGFR TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutation(s); squamous NSCLC after platinum chemotherapy
Product first approved 2013EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (16)
Non-Small Cell Lung Cancer
NCT06486142 · Region Skane
2022-09-21 – 2028-09 · Non-Small Cell Lung Cancer
What this study did
NCT01953913 · Boehringer Ingelheim
2013-09-30 – 2018-07-06 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02044380 · Boehringer Ingelheim
2014-03 – 2016-02 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01814553 · Boehringer Ingelheim
2013-04 – 2015-07 · Carcinoma, Non-Small-Cell Lung
What this study did
Other / comorbidity
NCT01427478 · Centre Leon Berard
2011-09 – 2021-05 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT01125566 · Boehringer Ingelheim
2010-06-22 – 2018-07-06 · Breast Neoplasms
What this study did
NCT01345682 · Boehringer Ingelheim
2012-01-05 – 2016-12-06 · Head and Neck Neoplasms, Carcinoma, Squamous Cell
What this study did
NCT01345669 · Boehringer Ingelheim
2011-10-17 – 2016-09-12 · Head and Neck Neoplasms
What this study did
NCT02131155 · Boehringer Ingelheim
2014-07-17 – 2016-08-22 · Head and Neck Neoplasms
What this study did
Phase 2/3 (1)
Other / comorbidity
NCT07653451 · Peking University Cancer Hospital & Institute
2026-07-01 – 2028-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
Phase 2 (96)
Non-Small Cell Lung Cancer
NCT06709859 · Shandong Public Health Clinical Center
2025-05-01 – 2027-12-31 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04497584 · University of Texas Southwestern Medical Center
2021-08-04 – 2027-09-01 · Advanced Squamous Non Small Cell Lung Cancer
What this study did
NCT06062823 · National University Hospital, Singapore
2024-03-25 – 2026-12 · NSCLC
What this study did
NCT05588609 · Partner Therapeutics, Inc.
2022-11-17 – 2025-07-03 · NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
What this study did
NCT03574402 · Guangdong Association of Clinical Trials
2018-07-09 – 2024-12-30 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01553942 · Massachusetts General Hospital
2012-04 – 2024-12 · Lung Cancer
What this study did
NCT05298176 · Amsterdam UMC, location VUmc
2022-01-04 – 2024-04-01 · Non-Small Cell Lung Cancer
What this study did
NCT04470076 · Fifth Affiliated Hospital, Sun Yat-Sen University
2020-07-10 – 2023-07-30 · Non Small Cell Lung Cancer, Surgery, EGFR Activating Mutation, Chemotherapy, EGFR TKI
What this study did
NCT02183883 · University College, London
2016-12-16 – 2023-03-22 · Non-small Cell Lung Cancer
What this study did
NCT03810872 · Universitair Ziekenhuis Brussel
2017-06-21 – 2022-12 · Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation
What this study did
NCT03727724 · The Netherlands Cancer Institute
2018-12-04 – 2022-09-06 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04201756 · Shanghai Pulmonary Hospital, Shanghai, China
2020-07-26 – 2022-08-30 · Lung Adenocarcinoma Stage III, EGFR Gene Mutation
What this study did
NCT01746251 · Massachusetts General Hospital
2013-01 – 2021-11 · Non Small Cell Lung Cancer
What this study did
NCT02716311 · Intergroupe Francophone de Cancerologie Thoracique
2016-05 – 2021-04-07 · Non Small Cell Lung Cancer
What this study did
NCT02470065 · European Organisation for Research and Treatment of Cancer - EORTC
2016-01 – 2021-01 · Non Small Cell Lung Cancer
What this study did
NCT03157089 · Boehringer Ingelheim
2017-11-02 – 2020-01-13 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01466660 · Boehringer Ingelheim
2011-12-13 – 2019-04-12 · Lung Neoplasms
What this study did
NCT01415011 · University College, London
2012-12 – 2018-11-30 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02597946 · Boehringer Ingelheim
2016-03-18 – 2018-07-22 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02488694 · AIO-Studien-gGmbH
2015-11 – 2017-12 · Non-small-cell Lung Cancer With Somatic EGFR Mutations
What this study did
NCT02595840 · Universität Duisburg-Essen
2015-11-25 – 2017-11-20 · Non-small-cell Lung Cancer With Somatic EGFR Mutations
What this study did
NCT02369484 · ETOP IBCSG Partners Foundation
2015-09-16 – 2017-09-15 · NSCLC
What this study did
NCT01542437 · Instituto Nacional de Cancerologia de Mexico
2012-01 – 2017-06 · Non-Small Cell Lung Cancer, EGFR, HER-2
What this study did
NCT02747953 · Samsung Medical Center
2011-07 – 2016-11 · Non-small Cell Lung Cancer
What this study did
NCT01932229 · Sheba Medical Center
2013-02 – 2015-01 · NSCLC
What this study did
NCT02625168 · The University of Hong Kong
2013-01 – 2014-12 · Lung Cancer
What this study did
NCT01880515 · Instituto Nacional de Cancerologia de Mexico
2010-12 – 2014-11 · Skin Rash, Lung Cancer
What this study did
NCT01480141 · Medical University of South Carolina
2012-01 – 2012-08 · Lung Cancer
What this study did
NCT00796549 · Boehringer Ingelheim
2008-12 – 2012-05 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT00730925 · Boehringer Ingelheim
2008-06 – 2012-01 · Carcinoma, Non-Small-Cell Lung
What this study did
Other / comorbidity
NCT02491099 · Yale University
2015-06 – 2028-12 · HER2/Neu+ Uterine Serous Carcinoma
What this study did
NCT05070403 · H. Lee Moffitt Cancer Center and Research Institute
2021-10-01 – 2028-03 · Squamous Cell Carcinoma
What this study did
NCT02465060 · National Cancer Institute (NCI)
2015-08-17 – 2027-12-31 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma, Colorectal Carcinoma, Endometrial Carcinoma, Esophageal Carcinoma, Exocrine Pancreas Carcinoma, Gastric Carcinoma, Glioma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Kidney Carcinoma, Liver Carcinoma, Lung Carcinoma, Lymphoma, Malignant Uterine Corpus Neoplasm, Malignant Uterine Neoplasm, Melanoma, Multiple Myeloma, Ovarian Carcinoma, Prostate Carcinoma, Rectal Carcinoma, Recurrent Bladder Carcinoma, Recurrent Breast Carcinoma, Recurrent Cervical Carcinoma, Recurrent Colon Carcinoma, Recurrent Colorectal Carcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Glioma, Recurrent Head and Neck Carcinoma, Recurrent Liver Carcinoma, Recurrent Lung Carcinoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Malignant Uterine Corpus Neoplasm, Recurrent Melanoma, Recurrent Multiple Myeloma, Recurrent Ovarian Carcinoma, Recurrent Pancreatic Carcinoma, Recurrent Prostate Carcinoma, Recurrent Rectal Carcinoma, Recurrent Skin Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma, Skin Carcinoma, Thyroid Gland Carcinoma
What this study did
NCT02925234 · The Netherlands Cancer Institute
2016-08 – 2027-12 · Cancer, Tumors, Neoplasm, Neoplasia
What this study did
NCT04439136 · National Cancer Institute (NCI)
2015-08-12 – 2027-03-03 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
What this study did
NCT06385483 · National Cancer Institute (NCI)
2018-02-28 – 2027-01-15 · Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
What this study did
NCT05865132 · AIPING ZHOU
2023-04-06 – 2026-04 · Esophagus Squamous Cell Carcinoma
What this study did
NCT05818982 · Peking University
2023-02-09 – 2026-02 · Advanced Esophageal Squamous Cell Carcinoma
What this study did
NCT02979977 · Yale University
2017-03-24 – 2026-01-18 · Squamous Cell Cancers of the Head and Neck
What this study did
NCT05519917 · Huashan Hospital
2022-10-01 – 2025-12-30 · Chordoma of Clivus
What this study did
NCT03088059 · European Organisation for Research and Treatment of Cancer - EORTC
2017-11-16 – 2025-12 · Carcinoma, Squamous Cell of Head and Neck
What this study did
NCT04183712 · Shanghai Jiao Tong University School of Medicine
2020-06-01 – 2025-12 · Gallbladder Carcinoma
What this study did
NCT03083678 · Leiden University Medical Center
2018-06-21 – 2025-01-31 · Chordoma
What this study did
NCT05516589 · West China Hospital
2022-09-12 – 2024-12-31 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT05517330 · West China Hospital
2022-09-19 – 2024-07-31 · Head and Neck Cancer
What this study did
NCT04839471 · National Health Research Institutes, Taiwan
2021-08-06 – 2024-06-19 · Esophageal Squamous Cell Carcinoma (ESCC)
What this study did
Phase 1/2 (10)
Non-Small Cell Lung Cancer
NCT02450656 · The Netherlands Cancer Institute
2015-06 – 2019-12 · Colorectal Neoplasms, Gastrointestinal Neoplasms, Pancreatic Neoplasms, Carcinoma, Non-Small-Cell Lung
What this study did
NCT01861223 · Samsung Medical Center
2013-05 – 2016-05 · NSCLC
What this study did
Other / comorbidity
NCT06085755 · Jeeyun Lee
2024-09-30 – 2028-12-01 · Stomach Neoplasm
What this study did
NCT06648096 · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
2024-11-08 – 2028-12 · Fanconi Anemia, Head and Neck Squamous Cell Carcinoma
What this study did
NCT06753747 · West China Hospital
2025-09-10 – 2028-09 · Esophagus Cancer
What this study did
NCT07010120 · West China Hospital
2025-06-10 – 2027-05-31 · HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy, Targeted Therapy
What this study did
NCT03785249 · Mirati Therapeutics Inc.
2019-01-15 – 2026-12-31 · Advanced Cancer, Metastatic Cancer, Malignant Neoplastic Disease
What this study did
NCT03481842 · BioGene Pharmaceutical Ltd.
2021-10-10 – 2021-10-10 · Endometriosis, Endometriosis Ovary, Endometriosis Externa, Endometriosis, Rectum
What this study did
NCT02372006 · Boehringer Ingelheim
2015-04-29 – 2020-08-05 · Neuroectodermal Tumors, Rhabdomyosarcoma
What this study did
NCT01732640 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2012-12 – 2017-01 · Squamous Cell Carcinoma of the Head and Neck
What this study did
Phase 1 (56)
Non-Small Cell Lung Cancer
NCT03827070 · Center Trials & Treatment Europe
2019-03-05 – 2023-07-21 · Non Small Cell Lung Cancer
What this study did
NCT04448379 · Shanghai JMT-Bio Inc.
2020-06-29 – 2022-06-30 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT03054038 · Vanderbilt-Ingram Cancer Center
2017-07-20 – 2022-03-23 · Non-Small Cell Lung Carcinoma
What this study did
NCT02364609 · Jonathan Riess
2015-09-30 – 2020-05-01 · Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer
What this study did
NCT03711422 · National Cancer Centre, Singapore
2018-11-16 – 2019-12-20 · Non-small Cell Lung Cancer, Leptomeningeal Disease, Central Nervous System Metastases
What this study did
NCT01999985 · H. Lee Moffitt Cancer Center and Research Institute
2013-12-31 – 2019-05-30 · Lung Cancer, Non-small Cell Lung Cancer (NSCLC)
What this study did
NCT02191891 · Boehringer Ingelheim
2014-10-21 – 2018-04-18 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02145637 · Yonsei University
2015-05-07 – 2017-11-09 · NSCLC
What this study did
NCT01647711 · Boehringer Ingelheim
2012-07 – 2015-09 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT01836341 · Memorial Sloan Kettering Cancer Center
2013-04 – 2015-04 · Non-small Cell Lung Cancer
What this study did
NCT01090011 · Boehringer Ingelheim
2010-03 – 2014-08 · Carcinoma, Non-Small-Cell Lung
What this study did
Other / comorbidity
NCT04185883 · Amgen
2019-12-17 – 2027-12-05 · Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
What this study did
NCT06302621 · Massachusetts General Hospital
2024-04-17 – 2027-12-01 · Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, Cholangiocarcinoma
What this study did
NCT05432518 · AHS Cancer Control Alberta
2023-06-27 – 2027-12-01 · Glioblastoma, Recurrent Disease, Recurrent Glioblastoma
What this study did
NCT06741982 · West China Hospital
2024-12-15 – 2026-12-15 · HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy, Targeted Therapy
What this study did
NCT06897735 · Petrov, Andrey
2025-11-09 – 2026-05-25 · Lung Cancer, Oral Cancer, Melanoma
What this study did
NCT05927844 · Fujian Cancer Hospital
2023-06 – 2025-06 · Esophageal Squamous Cell Carcinoma
What this study did
NCT06494189 · West China Hospital
2024-07-31 – 2025-04-10 · Head and Neck Cancer
What this study did
NCT05164848 · Peking University
2021-12-25 – 2023-10 · Esophageal Squamous Carcinoma
What this study did
NCT03652233 · Vanderbilt-Ingram Cancer Center
2018-11-02 – 2022-11 · Recurrent Squamous Cell Carcinoma of the Head or Neck, Metastatic Squamous Cell Carcinoma of the Head or Neck, Squamous Cell Carcinoma
What this study did
NCT02451553 · University of Washington
2015-11-05 – 2022-04-16 · Advanced Malignant Solid Neoplasm, Bile Duct Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer
What this study did
NCT02423525 · Santosh Kesari
2016-12 – 2021-08 · Brain Cancer
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT02975141 · PD Dr. med. Volker Heinemann
2016-09 – 2019-06 · Metastatic Pancreatic Cancer
What this study did
NCT01783587 · Dana-Farber Cancer Institute
2013-02 – 2018-06-01 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT01721525 · Memorial Sloan Kettering Cancer Center
2012-11 – 2017-10-16 · Head and Neck Cancer, Squamous Cell Cancer
What this study did
NCT00977431 · Boehringer Ingelheim
2009-09-17 – 2017-09-12 · Glioblastoma
What this study did
NCT01649271 · Boehringer Ingelheim
2012-07-23 – 2016-06-23 · Breast Neoplasms, Stomach Neoplasms
What this study did
NCT02020577 · Boehringer Ingelheim
2013-12 – 2016-04 · Neoplasms
What this study did
NCT01679405 · Johannes Gutenberg University Mainz
2012-08 – 2016-04 · Metastatic Disease
What this study did
NCT02216617 · Groupe Oncologie Radiotherapie Tete et Cou
2014-08-06 – 2015-09-15 · HNSCC
What this study did
NCT02096718 · Boehringer Ingelheim
2014-05 – 2014-12 · Renal Insufficiency
What this study did
NCT00998296 · Boehringer Ingelheim
2009-10 – 2014-07 · Neoplasms
What this study did
NCT00950742 · Boehringer Ingelheim
2009-08-01 – 2013-10-01 · Breast Neoplasms
What this study did
NCT01214616 · Boehringer Ingelheim
2010-10-01 – 2013-05-01 · Neoplasms
What this study did
NCT00906698 · Boehringer Ingelheim
2009-06 – 2013-01 · Neoplasms
What this study did
NCT01169675 · Boehringer Ingelheim
2010-07 – 2012-11 · Neoplasms
What this study did
NCT01298063 · Boehringer Ingelheim
2011-02 – 2012-01 · Liver Diseases, Healthy
What this study did
NCT01426958 · Boehringer Ingelheim
2011-08 – 2011-12 · Healthy
What this study did
NCT01396265 · Boehringer Ingelheim
2011-07 – 2011-08 · Healthy
What this study did
NCT02171754 · Boehringer Ingelheim
2009-09 – 2009-12 · Healthy
What this study did
NCT02171767 · Boehringer Ingelheim
2009-08 – 2009-10 · Healthy
What this study did
NCT00730821 · Boehringer Ingelheim
2007-01 – 2009-08 · Neoplasms
What this study did
NCT02171676 · Boehringer Ingelheim
2005-05 – 2008-03 · Neoplasms
What this study did
NCT02171741 · Boehringer Ingelheim
2005-04 – 2007-12 · Neoplasms
What this study did
Phase 4 (6)
Non-Small Cell Lung Cancer
NCT04413201 · Michael Hopp
2020-09-11 – 2026-12-31 · Non-squamous NSCLC
What this study did
NCT04814056 · Shanghai Chest Hospital
2021-06-01 – 2024-01-31 · NRG1-fused Non-small Cell Lung Cancer
What this study did
NCT02514174 · Boehringer Ingelheim
2015-08-18 – 2019-04-25 · Carcinoma, Non-Small-Cell Lung, ErbB Receptors
What this study did
NCT02208843 · Boehringer Ingelheim
2014-10-02 – 2017-06-13 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT02695290 · Boehringer Ingelheim
2016-03-17 – 2016-08-26 · Carcinoma, Non-Small-Cell Lung, ErbB Receptors
What this study did
Other / comorbidity
NCT04132102 · Shanghai Chest Hospital
2018-11-27 – 2021-08-31 · Lung Squamous Cell Carcinoma
What this study did
Early phase / not applicable (3)
Non-Small Cell Lung Cancer
NCT01074177 · Massachusetts General Hospital
2011-02 – 2017-03 · Non-small Cell Lung Cancer, EGFR Mutations
What this study did
NCT01776684 · Samsung Medical Center
2012-06 – 2015-05 · EGFR Mutation Positive Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT03908892 · Guangzhou University of Traditional Chinese Medicine
2019-06-12 – 2022-12 · Paronychia
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Non-Small Cell Lung Cancer
NCT06759857 · Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd.
2021-08-01 – 2025-05-01 · Non Small Cell Lung Cancer
What this study did
Appears in other studies (8)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2/3 (1)
Non-Small Cell Lung Cancer
NCT02438722 · SWOG Cancer Research Network
2015-05-07 – 2026-04-17 · Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
What this study did
Phase 2 (4)
Non-Small Cell Lung Cancer
NCT05215548 · National Taiwan University Hospital
2021-09-27 – 2027-10 · NSCLC Stage IV
What this study did
NCT01156545 · National Cancer Center, Korea
2010-10 – 2021-06-09 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT06804850 · West China Hospital
2025-01-20 – 2026-06-30 · Head and Neck Cancer
What this study did
NCT07040956 · West China Hospital
2025-06-28 – 2026-06-26 · Head and Neck Squamous Cell Carcinoma, Low-dose Radiotherapy, Immunotherapy, Targeted Therapy
What this study did
Phase 1/2 (2)
Non-Small Cell Lung Cancer
NCT06071013 · China Medical University Hospital
2024-02-23 – 2026-08-27 · Non-small Cell Lung Cancer, EGFR Gene Mutation, EGFR-TKI Resistant Mutation
What this study did
Other / comorbidity
NCT02768337 · Cambridge University Hospitals NHS Foundation Trust
2015-03-10 – 2021-08-12 · Lung Cancer, Breast Cancer, Brain Cancer, Advanced Breast Cancer, Advanced Lung Cancer
What this study did
Phase 1 (1)
Non-Small Cell Lung Cancer
NCT07271446 · Precision Biotech Taiwan Corp.
2018-09-01 – 2023-12-01 · Non-small Cell Lung Cancer
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Afatinib (Gilotrif): this drugApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Abp 234Phase 3Monoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PyrotinibPhase 3Small moleculeEGFR/HER1, HER2, HER4Partial signalNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 548 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Gilotrif (Afatinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 2HER2/Neu+ Uterine Serous CarcinomaRecruiting
Est. primary completion 2026-12 · NCT02491099 · CT.gov ↗
What to watch
Phase 1Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C MutationActive not recruiting
Est. primary completion 2026-12-17 · NCT04185883 · CT.gov ↗
What to watch
Phase 4Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT04413201 · CT.gov ↗
What to watch
2027 (9)
February 2027 (1)
Phase 2Squamous Cell CarcinomaActive not recruiting
Est. primary completion 2027-02 · NCT05070403 · CT.gov ↗
What to watch
May 2027 (1)
Phase 1/2HNSCC, Lysogenic HSV Virus, Neoadjuvant Therapy, Immunotherapy, Targeted TherapyActive not recruiting
Est. primary completion 2027-05-31 · NCT07010120 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1Glioblastoma, Recurrent Disease, Recurrent GlioblastomaEnrolling by invitation
Est. primary completion 2027-07-01 · NCT05432518 · CT.gov ↗
What to watch
September 2027 (2)
Phase 1/2Esophagus CancerRecruiting
Est. primary completion 2027-09 · NCT06753747 · CT.gov ↗
What to watch
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
December 2027 (4)
Phase 1Advanced Solid Tumor, Unresectable Solid Tumor, Metastatic Solid Tumor, CholangiocarcinomaRecruiting
Est. primary completion 2027-12-01 · NCT06302621 · CT.gov ↗
What to watch
Phase 1/2Stomach NeoplasmActive not recruiting
Est. primary completion 2027-12-01 · NCT06085755 · CT.gov ↗
What to watch
Phase 2Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma, Colon Carcinoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT02465060 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07653451 · CT.gov ↗
What to watch
2028 (2)
September 2028 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2028-09 · NCT06486142 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1/2Fanconi Anemia, Head and Neck Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-12 · NCT06648096 · CT.gov ↗
What to watch

See the full readout calendar ↗